Stocksigma LogoStocksigma Logo

Jubilant Therapeutics Reports Positive Phase 1 JBI-802 Data for ASH Presentation

Jubilant Pharmova subsidiary Jubilant Therapeutics announced an oral presentation of Phase 1/2 clinical data for lead asset JBI-802 at the 68th ASH Annual

Jubilant Therapeutics Reports Positive Phase 1 JBI-802 Data for ASH Presentation

Jubilant Pharmova Ltd · Press Release · 11 Nov 2026, 1:50 am

Jubilant Therapeutics Reports Positive Phase 1 JBI-802 Data for ASH Presentation Jubilant Pharmova subsidiary Jubilant Therapeutics announced an oral presentation of Phase 1/2 clinical data for lead asset JBI-802 at the 68th ASH Annual Meeting on 14th Dec'26. As of 30th Jun'26, 100% of patients (8/8) initiating the 15 mg dose achieved >50% platelet reduction or platelet normalization by Week 3, with a 15-day median response time. Normalization was maintained up to 46 weeks, with 7 of 11 leukocytosis patients achieving complete hematologic response and no dose-limiting toxicities observed across 5–15 mg cohorts.

Original exchange filing (PDF)

More announcements from Jubilant Pharmova Ltd

All Jubilant Pharmova Ltd announcements